• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20072 / SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine...

SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor

5 July 2007/in 2007, News

SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2007-07-05 13:17:372016-11-28 13:43:25SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen Announces First Meeting of Newly Formed Scientific Advisory Board Link to: SuperGen Announces First Meeting of Newly Formed Scientific Advisory Board SuperGen Announces First Meeting of Newly Formed Scientific Advisory Board Link to: 2007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Samples Link to: 2007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Samples 2007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Sample...
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok